

The Nomination Committee's statement and reasoning

This year's nomination committee consists of the chairman Peter Lindvall (representing Mikael Löfman, Mats Leifland (representing Mats Ohlin), and Ranny Davidoff (representing Ranny Davidoff), as well as Carl Borrebaeck as chairman of the board. Since the chairman of the board Carl Borrebaeck was one of the three largest shareholders Carl Borrebaeck, in his capacity as a shareholder, has made his seat available to the next shareholder, Carl Borrebaeck has chosen not to participate in the work of the nomination committee due to personal reasons.

The task of the Nomination Committee is to submit proposals for the Chairman and other Board members, as well as fees and other remuneration for Board and Committee assignments for each of the members. Furthermore, the Nomination Committee has to submit proposals for the election and remuneration of the auditors as well as proposals for a Chairman at the Annual General Meeting.

After the new share issue in April 2023, the ownership structure of Immunovia has changed. As this change took place less than three months before the Annual General Meeting, the Nomination Committee was not reconstituted.

The Nomination Committee's work

The Nomination Committee has held five meetings. In order to assess the degree to which the Board fulfills the requirements that are placed on the Board as a result of the company's current position and future direction, the Nomination Committee's discussions have focused on the Board's composition in terms of size, experience, expertise, diversity and an even gender distribution.

The Nomination Committee believes that the composition of the Board, taking into account the business that the company conducts and the continued expansion phase that the company is in, is good in terms of the experience and expertise of the Board members.

Proposal for Chairman at the Annual General Meeting

As Chairman of the meeting, the Nomination Committee proposes lawyer Fredrik Önnarfors, active at Prolegal.

Proposal regarding the number of Board members and deputy Board members, remuneration to the Board

The number of Board members proposed is five. No deputies shall be appointed.

The proposed fee to be paid to the Board is a total of SEK 1,510,000, with SEK 550,000 to go to the Chairman and SEK 240,000 to each of the other Board members elected by the Annual General Meeting who are not employed by the company. The Nomination Committee believes that the proposed fees are market-based.

Furthermore, it is proposed that the Board members be compensated for reasonable travel expenses in accordance with the company's policy.

It is proposed that the Chairman of the Audit Committee and the Remuneration Committee be remunerated with SEK 50,000 and the other members of said committees to be remunerated with SEK 30,000.

Proposals regarding the election of Board members and Chairman of the Board

For board members, the re-election is proposed of board members Philipp von Hugo and Peter Høngaard Andersen as well as the new election of Vanessa Rollings, Helge Lubenow and Sven Andréasson for the period until the end of the next Annual General Meeting.

After having founded the company and been Immunovia's Chairman of the Board since the start in 2007, Carl Borrebaeck has chosen not to stand for re-election of his own accord at the Annual General Meeting, and thereby leave Immunovia's Board in order to increase his involvement in his other development companies. Martin Möller, Eric Krafft and Hans Johansson have declined re-election. It is proposed that Peter Høngaard Andersen be elected Chairman of the Board.

Vanessa Rollings

Vanessa Rollings is a senior financial executive with over 25 years of experience assisting healthcare, technology, and consumer & retail companies scale their business. Vanessa's career reflects a demonstrated track record of building and developing high-functioning finance and accounting teams, leading corporate development, raising capital, rapidly growing revenues, building out a business intelligence function, managing investor relations, and executing M&A transactions in domestic and global markets. Vanessa is currently CFO of Big Health, a privately-held digital therapeutics company providing safe and effective non-drug alternatives for the most common mental health conditions. Previously, Vanessa was the Chief Financial Officer of Tempus Labs, Inc., a privately-held, data driven precision medicine company. She has held CFO roles at three other companies, including a consulting firm with ~\$100 million in annual revenues and a health-tech venture capital firm. Prior to her CFO roles, Vanessa was an investment banker focused on sell-side mergers & acquisitions at William Blair. Vanessa has an MBA in finance and marketing from the Kellogg School of Management at Northwestern University and a Bachelors of Business Administration from the University of Notre Dame.

Vanessa Rollings är oberoende i förhållande till bolaget, bolagsledningen och bolagets större aktieägare. Holdings Immunovia: 0 shares.

Helge Lubenow

Dr. Helge Lubenow (*1968, German) studied Biology and earned the doctoral degree at the University of Cologne and the Max-Planck-Institute in the field of genetics.

After joining Qiagen GmbH, Germany, in 1997, Dr. Lubenow held various positions, most recently Senior Vice President, Head of Molecular Diagnostic Business. During this time, Dr. Lubenow also assumed positions in enterprises newly acquired by

Qiagen GmbH, such as Corbett Life Science, Sydney, Australia and Digene Inc., Gaithersburg, U.S.A. and was responsible for integration of the respective enterprise. In 2016, Dr. Lubenow founded her own consulting firm AGOS Consulting. From 2018 to 2019 she was the managing director of tesa Labtec GmbH a manufacturer of pharmaceutical special dosage forms. In January 2020 she was appointed as CEO of Proteomedix AG, Zurich, Switzerland, an organization engaged in prostate cancer diagnostics for which she had served as a member of the board since 2017. Dr. Lubenow has many years of experience in the field of molecular diagnostics within a broad network in the health sector, in management consulting and is an expert for the in vitro diagnostics industry in Europe, Asia and the United States

Dr. Lubenow is an independent member (within the meaning of the German Corporate Governance Code) of the legally required supervisory boards of the following companies: Biofrontera AG, Leverkusen, Germany (since December 2021); Epigenomics AG, Berlin, Germany (since June 2016).

Dr. Lubenow is a member of the following comparable control committees of domestic and foreign companies: Neracare GmbH, Frankfurt am Main, Germany; Human Gesellschaft für Biochemica und Diagnostica mbH, Wiesbaden, Germany; Avelo AG, Schlieren, Switzerland.

Helge Lubenow is independent in relation to the company, the company's management and the company's major shareholders. Shareholding in Immunovia: 0 shares.

Sven Andréasson

Sven Andréasson has more than 40 years' experience as an executive in the life science industry. He started his career at Kabi, Stockholm, where he became CEO for the German, UK and Belgian subsidiaries. He subsequently became head of the Biopharmaceutical division responsible for human growth hormones, blood plasma products, and LMW heparin/ thrombolytic cardiovascular products. After the acquisition of Pharmacia in 1989 he became President of Pharmacia International in Brussels, Belgium and later Pharmacia SA, Paris, France (today part of Pfizer). From 1999 he served for nine years as the President and CEO of Active Biotech, Lund Sweden, a publicly traded company developing innovative products for autoimmune diseases including multiple sclerosis (partnered with TEVA) and for various cancers. He subsequently became CEO of Beta-Cell NV, in Brussels, a company developing cell-based treatments for diabetes. In February 2012 he became CEO of Isconova AB, a vaccine development company acquired by Novavax Inc, MD, USA where he is Senior VP, Business & Corporate Development. Sven Andréasson has an MSc in business administration and finance from the Stockholm School of Economics..

Sven Andreasson is independent in relation to the company, the company's management and the company's major shareholders. Shareholding in Immunovia: 0 shares.

It is the opinion of the Nomination Committee that the proposed Board has the appropriate composition, characterized by versatility and breadth in terms of expertise, experience and background. The Nomination Committee can state that the members of the Board meet the goal of an even gender distribution applicable to Swedish listed companies. The Nomination Committee has also made an assessment of each member's ability to devote sufficient time and commitment to the Board assignment.

Vanessa Rollings, Helge Lubenow, Sven Andréasson, Peter Høngaard Andersen and Philipp von Hugo are independent in relation to the company, the company's management and the major shareholders in the company.

Proposals regarding the selection of auditors and remuneration to the auditor

The Nomination Committee proposes, following a recommendation from the Audit Committee, that the meeting elect the authorized accountant Mats-Åke Andersson of HLB Auditoriet AB, as auditor for the company, with the authorized accountant Martin Gustafsson of HLB Auditoriet AB, as deputy auditor.

It is proposed that fees to the auditors be paid according to an approved invoice.

Proposal regarding the nomination committee for next year's Annual General Meeting

The Nomination Committee does not propose any changes to the principles for the appointment and work of the Nomination Committee passed at the 2018 Annual General Meeting.

Lund, April 18, 2023

The Nomination Committee of Immunovia AB (publ)